Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY : Is empirical triple therapy justified ?
Among patients with peptic ulcer disease, the prevalence of Helicobacter pylori has been reported to range from 80% to 90%. Thus empirical cost-effective therapy has been suggested.
We surveyed patients with peptic ulcer disease in Rochester, NY.
From two teaching hospitals all patients who had duodenal ulcers (DU) and/or gastric ulcers (GU) on esophagogastroduodenoscopy (EGD) with antral biopsy for histology for H. pylori and for rapid urease (CLO) test were included in the study.
We examined a total of 160 patients with DU and 145 patients with GU, age range 18-92 yr, obtaining clinical data, race, medication profile, and history of use of nonsteroidal antiinflammatory drugs (NSAIDs).
An ulcer was defined if the lesion with loss of mucosal integrity was = 0.5 cm, with apparent depth.
H. pylori was considered present if CLO test and/or histology were positive for H. pylori.
To confirm the reliability of nonuse of NSAIDs, we randomly checked blood samples of 90 such patients from the ambulatory clinic for the presence of salicylates.
To identify the sensitivity of the CLO test, we performed a serology test for H. pylori antibody in 100 subjects to compare the CLO test results.
Also, 500 CLO test results were compared to the histology results for H. pylori.
Among 160 DU patients, 16 were NSAID users with negative H. pylori and excluded from the prevalence study.
Of the remaining 144 patients with DU, H. (...)
Mots-clés Pascal : Ulcère, Gastroduodénal, Incidence, Gastrite, Bactériose, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bactérie, Indication, Chimiothérapie, Multiple, Antibactérien, Antisécrétoire, Evaluation performance, Homme, Appareil digestif pathologie, Estomac pathologie, Intestin pathologie
Mots-clés Pascal anglais : Ulcer, Gastroduodenal, Incidence, Gastritis, Bacteriosis, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bacteria, Indication, Chemotherapy, Multiple, Antibacterial agent, Antisecretory agent, Performance evaluation, Human, Digestive diseases, Gastric disease, Intestinal disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0248452
Code Inist : 002B05B02F. Création : 11/09/1998.